To prevent the development of advanced liver dysfunctions, such as liver cirrhosis, hepatocellular carcinoma, and liver failure, antiviral therapies using pegylated interferon (PEG-IFN) and/or nucleotide/nucleoside analogs (NAs) are conducted to treat chronic hepatitis and liver cirrhosis caused by chronic HBV infection [2,3,4]. Here, IFNA1 is linked to cirrhosis of liver.